Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 8.4% – Should You Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE) shot up 8.4% on Wednesday . The stock traded as high as $36.50 and last traded at $36.02. 328,145 shares were traded during mid-day trading, an increase of 6% from the average session volume of 308,758 shares. The stock had previously closed at $33.23.

Wall Street Analysts Forecast Growth

MAZE has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. BTIG Research upped their price target on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, September 12th. JPMorgan Chase & Co. increased their price target on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, September 29th. Guggenheim boosted their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, September 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Maze Therapeutics in a research note on Thursday, September 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $38.57.

Maze Therapeutics Stock Performance

The stock has a market cap of $1.70 billion and a P/E ratio of -1.69. The stock has a 50-day moving average price of $28.24 and a 200-day moving average price of $18.46.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In other news, Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Investors Weigh In On Maze Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund purchased a new position in shares of Maze Therapeutics in the 1st quarter worth about $25,000. CWM LLC bought a new stake in Maze Therapeutics in the 2nd quarter worth approximately $28,000. Ameritas Investment Partners Inc. boosted its stake in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares in the last quarter. Corebridge Financial Inc. bought a new position in Maze Therapeutics during the first quarter valued at approximately $48,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares in the last quarter.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.